NICE, the health technology assessment (HTA) body for England and Wales, has decided not to re-appraise Janssen’s nasal spray for treatment-resistant major depression (TRD), Spravato (esketamine), prompting its parent company Johnson & Johnson to criticize NICE’s assessment process for mental health therapies.
“The level of evidence available for mental health treatments is not on par with physical health evidence; with less data...







